Inrebic (fedratinib) — United Healthcare
myeloid/lymphoid neoplasms with eosinophilia and JAK2 rearrangement
Initial criteria
- Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia
- AND
- Patient has a JAK2 rearrangement
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inrebic therapy
Approval duration
12 months